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In Parkinson disease (PD), a-synuclein aggre-
gates called Lewy bodies often involve and se-
quester Septin4 (Sept4), a polymerizing scaffold
protein. However, the pathophysiological signif-
icance of this phenomenon is unclear. Here, we
show the physiological association of Sept4
witha-synuclein, the dopamine transporter, and
otherpresynapticproteins indopaminergicneu-
rons; mice lacking Sept4 exhibit diminished do-
paminergicneurotransmissiondue toscarcityof
these presynaptic proteins. These data demon-
strate an important role for septin scaffolds in
thebrain. In transgenicmice thatexpresshuman
a-synucleinA53T (a mutant protein responsible
for familial PD), loss of Sept4 significantly en-
hances neuropathology and locomotor deterio-
ration. In this PD model, insoluble deposits of
Ser129-phosphorylateda-synucleinA53T are neg-
atively correlated with the dosage of Sept4.
In vitro, direct association with Sept4 protects
a-synuclein against self-aggregation and
Ser129 phosphorylation. Taken together, these
data show that Sept4 may be involved in PD as
a dual susceptibility factor, as its insufficiency
can diminish dopaminergic neurotransmission
and enhance a-synuclein neurotoxicity.
INTRODUCTION
Septins are polymerizing GTP binding proteins that serve
as scaffolds for diverse molecules beneath the plasmaNmembrane (Field and Kellogg, 1999; Versele and Thorner,
2005; Kinoshita, 2006). In addition to playing roles in mito-
sis (Kinoshita et al., 1997, Surka et al., 2002; Spiliotis et al.,
2005), mammalian septins are abundant in the central ner-
vous system (CNS) (Kinoshita et al., 1998, 2000; Xue et al.,
2004; Hall et al., 2005), where they have been implicated in
exocytosis (Hsu et al., 1998; Beites et al., 1999, 2005; Xue
et al., 2004). However, it is not clear whether and how sep-
tins are involved in exocytosis and/or neurotransmission
in vivo, partly because mice that lack Sept3, Sept5, or
Sept6 do not show obvious CNS abnormalities (Fujishima
et al., 2007; Peng et al., 2002; Ono et al., 2005).
Meanwhile, septins have been implicated in diverse
neurodegenerative disorders in humans. For instance,
mutations in the Sept9 gene were found in hereditary neu-
ralgic amyotrophy (Kuhlenbaumer et al., 2005). Sept4 and
two other septins were found in neurofibrillary tangles in
Alzheimer’s disease (Kinoshita et al., 1998). Sept4 coag-
gregates with a-synuclein in cytoplasmic inclusion bodies
known as Lewy bodies (LBs) in sporadic Parkinson dis-
ease (PD) and dementia with Lewy bodies and in glial
cytoplasmic inclusions in multiple system atrophy (Ihara
et al., 2003). Sept4 and Sept5/CDCrel-1 are substrates
for a ubiquitin ligase, parkin; hence, loss of parkin function
may result in accumulation of these paralogous septins
(Zhang et al., 2000b; Choi et al., 2003; Son et al., 2005).
Intriguingly, acute overload of Sept5 can be both inhibitory
to exocytosis and neurotoxic (Beites et al., 1999; Dong
et al., 2003; Son et al., 2005). However, it is not clear
whether the toxicity of septin overload or loss of septin
function plays important roles in the pathogenesis of
a-synucleinopathies.
This study was designed to address physiological and
pathological roles of Sept4 in normal and PD brains. We
first examined the status of Sept4 in sporadic PD cases
and found that it was often deficient in dopaminergiceuron 53, 519–533, February 15, 2007 ª2007 Elsevier Inc. 519
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Septin, Dopamine Neuron, and a-Synucleinopathy(DA) nerve terminals in the striatum. This prompted us
to explore the consequences of Sept4 deficiency in
Sept4/ mice, and our comprehensive screening pin-
pointed a specific attenuation of their nigrostriatal DA
transmission without affecting the neuronal morphology.
We found that Sept4 is required for DA neurons to main-
tain key components of DA metabolism. Transgenic
supplementation of Sept4 was sufficient to rescue the bio-
chemical deficits in Sept4/ striatum. Finally, we tested
whether Sept4 deficiency couldmodify a-synucleinopathy
in transgenic mice expressing human a-synucleinA53T,
a pathogenic mutant responsible for a trait of familial PD
(Giasson et al., 2002). Surprisingly, genetic loss of Sept4
in this PD model exacerbated neuronal loss, gliosis, and
locomotor deterioration, which were accompanied by
severe amyloid deposits containing Ser129-phosphory-
lated a-synucleinA53T. In vitro, Sept4 interfered with self-
aggregation and Ser129 phosphorylation of a-synuclein.
These results suggest that physiological interaction with
Sept4 prevents a-synuclein from converting into neuro-
toxic species and aggregates, and that DA neurons
deficient in Sept4 becomemore susceptible to further dys-
function and degeneration in PD.
RESULTS
Physiological Localization of Sept4 in Presynaptic
Dopaminergic Terminals in Human Striatum
and Its Depletion in Parkinson Disease
In agreement with our previous observations (Ihara et al.,
2003), antibodies raised against three distinct epitopes
of Sept4 consistently labeled LBs in the substantia nigra
pars compacta (SNpc) of all sporadic PD cases examined
(n = 5; Figures 1B and 1D, and data not shown). Sept4 and
a-synuclein colocalized in the core of LBs (Figures 1C and
1D), indicating their close relationship. In contrast, anti-
bodies for five other septins including Sept5/CDCrel-1
(a substrate for parkin) did not label LBs (Figure 1A
and data not shown). These data confirmed the specific
involvement of Sept4 in a-synuclein aggregates in PD.
In control human brains without PD, Sept4 was abun-
dant in presynaptic terminals of DA neurons projecting
from SNpc to the striatum (putamen). Sept4 was colocal-
ized in the varicosities with the dopamine transporter (DAT
in Figures 1E–1G) and a-synuclein (aS in Figures 1H–1J).
These data suggest physiological association of Sept4
with these presynaptic molecules in DA nerve terminals.
To examine the status of presynaptic Sept4 in PD, we
measured the content of Sept4 in the putamen by immu-
nohistochemistry and immunoblot. In non-PD controls,
immunohistochemical signals for Sept4 were more in-
tense in the putamen than in the adjacent cerebral (insular)
cortex (Figures 1K and 1S), while in PD, Sept4 was recog-
nizably reduced in the putamen (Figures 1L and 1S). The
deficiency of Sept4 was comparable with that of DAT in
the adjacent slices (Figures 1Q and 1R). The relative den-
sitometric values for Sept4 in the putamen (Dpu) and insu-
lar cortex (Dcx) could segregate PD cases from non-PD520 Neuron 53, 519–533, February 15, 2007 ª2007 Elsevier Inccontrols (Figure 1M, n = 12). In contrast, a general presyn-
aptic marker, synaptophysin, was not reduced in PD puta-
men (Figures 1N–1P, n = 8). Consistently, immunoblot
analysis demonstrated that Sept4 was often reduced in
PD specifically in the putamen but not in the cerebral cor-
tex (Figures 1T–1W and Figure S1 in the Supplemental
Data). Considering the heterogeneous etiology of spo-
radic PD and the variability of individual human samples,
Sept4 deficiency in the striatum is regarded as one of
the common pathological changes in PD.
Loss of Sept4 Attenuates Dopaminergic
Transmission in the Mouse
To address the physiological significance of Sept4 in the
CNS, we examined the distribution of Sept4 and the im-
pact of its loss in the mouse. Using in situ hybridization
and immunohistochemistry techniques, it was demon-
strated that Sept4 was expressed in specific cell popula-
tions in the cerebral cortex, striatum, midbrain, cerebel-
lum, and spinal cord (Figures 2A–2E, Figure S9, and
data not shown). As with DA neurons, Sept4 was present
in the cell bodies in the SNpc and ventral tegmental area
(VTA) (Figure 2D), in projection fiber bundles (arrows in
Figures 2B and 2E), and in axon terminals surrounding
striatal neurons (Figure 2E). As seen in the human brain,
Sept4, a-synuclein, and DAT were abundant and colocal-
ized in the axon terminals, especially at the varicosities
(Figures 2F–2K).
We generated Sept4/ mice with a genetic back-
ground of C57BL/6J, all of which appeared normal except
for unexpected male infertility (Ihara et al., 2005). All the
Sept4 polypeptides were abolished in Sept4/ brain (Fig-
ures 2A–2C). Given the widespread distribution of Sept4
in the CNS, we performed a comprehensive physical
and behavioral screening (Supplemental Figures S2–S5).
Sept4/ mice were normal except for a paradigm of pre-
pulse inhibition of the acoustic startle response (PPI). This
paradigm is an index of reduction in startle amplitude to
a loud acoustic stimulus when the stimulus is preceded
by a moderate prestimulus (Figure 3A). Sept4/ mice
exhibited a lower basal startle response and a significant
enhancement in PPI (Figure 3B; p = 0.0011). Since DA an-
tagonists can enhance PPI (Zhang et al., 2000a), we sus-
pected attenuated DA transmission in Sept4/mice. The
mice were challenged with apomorphine at a low dose
(0.05mg/kg) that is known to block DA transmission by se-
lectively stimulating DA presynaptic autoreceptors (Starke
et al., 1989). PPI was enhanced in Sept4+/+ mice but dis-
rupted in Sept4/ mice (the differences between Figures
3B and 3C are indexed in Figure 3D). However, a higher
dose of apomorphine (3 mg/kg), which dominantly stimu-
lates postsynaptic DA receptors, disrupted PPI in both ge-
notypes (Supplemental Figure S6). Thus, the attenuated
DA transmission in Sept4/ mice was attributed to pre-
synaptic (rather than postsynaptic) defects.
To confirm this, we reassessed spontaneous locomotor
activity in an open field (as in Supplemental Figure S5)
with methamphetamine, which releases DA from the.
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Septin, Dopamine Neuron, and a-SynucleinopathyFigure 1. Involvement of Sept4 in Sporadic Parkinson
Disease: Sequestration in Nigral Lewy Bodies and Depletion
in the Striatum
(A and B) Nigral DA neurons bearing LBs in human brains affected with
sporadic PD. LBs (arrows), surrounded by neuromelanin granules
(dark brown deposits), were not labeled for Sept5 (A), but were consis-
tently labeled for Sept4 (light brown signal in B). Bars, 20 mm.
(C and D) Two adjacent sections showing a DA neuron with an LB (ar-
rows) containing both a-synuclein (aS) (C) and Sept4 (D). Bars, 20 mm.
(E–G) The normal human striatum labeled for Sept4 ([E], red) and the
dopamine transporter (DAT) ([F], green) and the merged image [G].Nepresynaptic terminals (Hyman et al., 2006).While the basal
activity and methamphetamine-driven hyperactive surge
were almost normal in Sept4/ mice, their hyperactivity
decayed more rapidly (Figure 3E, p < 0.05). These data
indicate a presynaptic cause of the attenuated DA trans-
mission in Sept4/ striatum.
In addition, DA content was significantly reduced in
Sept4/ striatum by 25% (Figure 6G; p = 0.039), indi-
cating a requirement of Sept4 for DA metabolism.
Dopaminergic Axon Terminals in Sept4/ Striatum
Are Morphologically Normal but Deficient in Key
Molecules for Dopamine Metabolism
Based on the behavioral pharmacology data, we exam-
ined the status of nigral DA neurons by immunohisto-
chemistry for tyrosine hydroxylase (TH), the rate-limiting
enzyme of DA synthesis. In the midbrain, the number
and morphology of TH-positive neuronal somata were
comparable between Sept4+/+ and Sept4/ mice
(Supplemental Figure S7). However, Sept4/ striatum
was labeled less intensely for TH and DAT (Figure 4A).
Quantitative morphometric analyses of TH/DAT-positive
axons and axon terminals at both the light microscopy
level (Figure 4B) and EM level (Figure 4C and Supplemen-
tal Figure S8) could not discriminate the two genotypes.
In immunoblot, the densitometric ratios of TH and DAT
against synapsin IIa or glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were significantly reduced in
Sept4/ striatum (by 30% and 55%, respectively),
Arrows indicate presynaptic varicosities where intense signals of
Sept4 and DAT colocalize. Bar, 20 mm.
(H–J) The normal human striatum labeled for Sept4 ([H], red) and
a-synuclein ([I], green) and the merged image (J). Sept4 also colocal-
ized with a-synuclein in presynaptic varicosities (arrows). Bar, 20 mm.
(K and L) Representative images of Sept4 immunohistochemistry in
coronally sectioned human brains without (K) and with (L) sporadic
PD. Bars, 5 mm.
(M) Semiquantification of the Sept4 signal in the putamen with spo-
radic PD (n = 6) and without (n = 6). The relative abundance of Sept4
in the striatum is represented by an index, (Dpu-Dcx)/Dcx, where
Dpu and Dcx are the densitometric values of Sept4 in the putamen
and insular cortex, respectively.
(N–P) Relative striatal content of synaptophysin (Sph), a presynaptic
marker protein, was analyzed as in (M). Unlike Sept4, synaptophysin
was not depleted from the striatum in PD. Bars, 5 mm.
(Q and R) Immunohistochemistry of DAT in a non-PD (Q) and a PD (R)
brain, showing depletion of DAT from the striatum in PD. Bars, 5 mm.
(S) An anatomical diagram of the human basal ganglia (coronal sec-
tion). Cx, insular cortex; CL, claustrum; Pu, putamen; GPe/GPi, exter-
nal/internal pallidum; IC, internal capsule.
(T and U) Relative content of Sept4 was quantified by immunoblot
in the putamen of sporadic PD (n = 10) and non-PD (n = 10) brains.
The densitometric ratio of Sept4/synaptophysin (Sph) was frequently
reduced in the striata of the PD patients.
(V and W) Relative content of Sept4 was quantified by immunoblot in
the frontal cortex of sporadic PD (n = 5) and non-PD (n = 5) brains.
The densitometric ratio of Sept4/GAPDH was not reduced in the cere-
bral cortices of the PD patients. These data also exclude a possibility
that Sept4 is subject to postmortem protein degradation.uron 53, 519–533, February 15, 2007 ª2007 Elsevier Inc. 521
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shown). However, five postsynaptic parameters we exam-
ined were unaffected (Figures 4H and 4I, Figure 6D, and
Figure 2. Expression of Sept4 in the Mouse Brain
(A) Immunoblot of mouse brain extracts for Sept4. Four Sept4 prod-
ucts were detected in most parts of the brain to a varying degree
and were abolished in Sept4/ mice. Each lane contained 50 mg
protein.
(B and C) Sept4 immunohistochemistry (brown signals) in parasagittal
sections of Sept4+/+ and Sept4/ forebrains. The left and top in the
figures are the rostral and dorsal aspects, respectively. Projection fiber
bundles containing the nigrostriatal pathway are indicated by arrows in
(B) and dotted arrows in (C). CCx, cerebral cortex; St, striatum; SNpc,
substantia nigra pars compacta; SNpr, substantia nigra pars reticu-
lata; Th, thalamus; Hip, hippocampus. Bars: 1.5 mm.
(D) Sept4 immunohistochemistry using nickel enhancement (blue sig-
nals) in a coronal section of Sept4+/+ ventral midbrain. Sept4 was de-
tected in neuronal cell bodies in the ventral tegmental area (VTA; black
arrows) and SNpc (white arrows). Ml, medial lemniscus. Bar: 20 mm.
(E) A parasagittal section of Sept4+/+ striatum. Note Sept4-containing
(brown) puncta in the axon bundles (arrows) and their terminals sur-
rounding the target neurons (asterisks). Bar: 20 mm; inset, 10 mm.
(F–K) Double-label immunofluorescence of presynaptic terminals in
Sept4+/+ striatum. Sept4 signals ([F and I], red) were partially overlap-
ped with those of a-synuclein ([G], green), and DAT ([J], green). Bars:
10 mm (H and K).522 Neuron 53, 519–533, February 15, 2007 ª2007 Elsevier Inc.data not shown). These data indicate that loss of Sept4 di-
rectly or indirectly reduces the concentration of TH and
DAT in DA axons and axon terminals without affecting
their morphology. The scarcity of the two essential mole-
cules for DA metabolism may well account for the hypo-
dopaminergic phenotype observed in Sept4/ mice.
Transgenic Supplementation of Sept4 Can Restore
the Deficiency of TH and DAT in Sept4/ Mice
In the next series of experiments, we examined whether
Sept4 can rescue the deficiency of TH and DAT in
Sept4/ mice. For these purposes, we generated two
lines of transgenic mice, Sept4-Tg1 and Sept4-Tg2,
each harboring 10 transcription units of Sept454 kDa
cDNA driven by the prion promoter. The heterozygous
Tg mice were lean (25% body weight reduction), short-
lived, and barely fertile. These defects seemed to be due
to the nonspecific cytotoxicity of Sept4 overload (Ihara
et al., 2003; Dong et al., 2003) and ectopic Sept4 expres-
sion in the heart, adrenal gland, and germ cells (see
Discussion). Crossbreeding of Sept4-Tg1 and Sept4/
mice rarely generated live Sept4KO/Tg1 mice that ex-
pressed Sept454 kDa and shorter processed forms in the
striatum. Sept4KO/Tg1 striatum contained normal levels
of TH and DAT (Figures 5A and 5B). Although Sept4KO/
Tg2 mice were never born, Sept4-Tg2 mice showed
hyper-dopaminergic behaviors (Figures 5C and 5D) and
supernormal levels of TH and DAT (data not shown).
Although the primary effects from the loss or excess of
Sept4 may be complicated by compensatory and adap-
tive changes, these data consistently indicate a positive
role for Sept4 in DA metabolism.
Sept4 Is Required as a Component of the
Presynaptic Machinery for DA Turnover
To determine the molecular mechanism underlying the
hypo-dopaminergic phenotype of Sept4/ mice, we im-
munoprecipitated striatal homogenates of Sept4+/+ mice
with anti-Sept4 antibodies, then immunoblotted for possi-
ble Sept4-interacting molecules. Consistent with our pre-
vious report (Ihara et al., 2003) and the colocalization data
(Figures 1G and 1J and Figures 2H and 2K), Sept4 was
coimmunoprecipitated with DAT and a-synuclein (Figures
6A and 6B). Since Sept5, the closest paralog of Sept4, has
been implicated in syntaxin (Stx)-mediated exocytosis
(Beites et al., 1999), we tested the interaction between
these septins and Stx-1A. Sept5 and Stx-1A were coim-
munoprecipitated from the cerebellar cortex, but not
from the striatum (data not shown). In contrast, Sept4
and Stx-1A were reciprocally coimmunoprecipitated
from the striatum (Figures 6A and 6C). However, a compo-
nent of the exocyst complex, Sec8, and a postsynaptic
protein, mGluR1, were present in the striatum but did
not immunoprecipitate with Sept4 (Figure 6A). These
data indicate a physiological association of Sept4 with
presynaptic molecules involved in DA release and reup-
take. Given the individual associations between a-synu-
clein and DAT (Lee et al., 2001), and Stx-1A and DAT
Neuron
Septin, Dopamine Neuron, and a-SynucleinopathyFigure 3. Sept4/ Mice Exhibit Hypo-Dopaminergic Abnor-
malities in Prepulse Inhibition and Methamphetamine-
Induced Locomotor Response
(A) (Top) The measurement of PPI of acoustic startle response. (Bot-
tom) PPI is defined here as the percent reduction in the amplitude of
the startle response to a loud stimulus (pulse) when it is preceded by
a moderate prestimulus (prepulse).
(B) The startle response amplitude to a 110 dB stimulus (left) and PPI
(right) after a mock pretreatment with saline. As compared with
Sept4+/+ littermates, Sept4/ mice showed significant enhancement
in PPI by a prepulse of 74 or 78 dB (n = 15 per genotype).
(C) The startle amplitude to the 110 dB stimulus (left) and PPI (right) af-
ter a pretreatment with a DA agonist, apomorphine (0.05 mg/Kg s.c.).N(Lee et al., 2004), our results point to a larger protein
complex in the striatum that contains Sept4, a-synuclein,
Stx-1A, and DAT.
Septins often serve as scaffolds that anchor and/or sta-
bilize other molecules. Depletion of cellular septins by
RNAi reduces the amount of binding partners in the
same complex (Kinoshita et al., 2002). Thus, we examined
whether the loss of Sept4 also affects interaction partners
other than DAT. In Sept4/ striatum, the contents of Stx-
1A, SNAP25, Munc18, and a-synuclein were slightly but
consistently reduced, while that of Vesl-1L, a postsynaptic
protein, was not affected (Figures 6D–6F). (Note: we pre-
dict the deficiencies of Stx-1A and a-synuclein in DA
neurons were underestimated by this method; these
molecules are also expressed in other cells that do not
express Sept4, and are hence unaffected by the loss of
Sept4.)
The biochemical evidence, along with the colocalization
and behavioral data, strongly suggests that Sept4 is
closely associated with the key molecules for DA metabo-
lism. Considering the normal morphology of Sept4/ DA
neurons (Figures 4B and 4C and Supplemental Figure S8),
Sept4 may be required not as a cytoskeletal protein, but
as a component of a presynaptic scaffold that directly or
indirectly supports the molecular machinery for dopamine
turnover.
Loss of Sept4 Exacerbates Neuropathology
of a-SynucleinA53T Transgenic Mice
Next, we focused on pathological interaction between
Sept4 and another molecule in the DA terminals, a-synu-
clein. We have so far demonstrated their physiological as-
sociation and pathological coaggregation in a-synucleino-
pathies (Ihara et al., 2003; and Figures 1B–1D, Figure 2H,
and Figures 6A, 6B, 6D, and 6F). To critically test whether
the interaction with Sept4 promotes or suppresses ag-
gregation and neurotoxicity of a-synuclein, we utilized
Sept4/ mice. We also employed a transgenic mouse
model of a-synucleinopathy, in which human a-
synucleinA53T (a mutant protein responsible for a trait of
familial PD) is expressed by the prion promoter (Giasson
et al., 2002). As reported, biallelic a-synucleinA53T trans-
genicmice (aStgmice) developed locomotor deterioration,
Presynaptic DA blockade by apomorphine enhanced PPI in Sept4+/+
mice (as seen in Sept4/ mice in B), whereas it paradoxically disrup-
ted PPI in Sept4/ mice.
(D) Comparison of the apomorphine-induced PPI changes by geno-
type.
(E) Methamphetamine-induced hyperactivity was not sustained in
Sept4/mice. Spontaneous activities of Sept4+/+ and Sept4/ litter-
mates were automatically measured in an open field setup. After a
habituation, methamphetamine (MAP, 3 mg/Kg, i.p.) was injected at
t = 60 (min, arrow). Although the basal and peak activities of Sept4/
mice were almost normal, locomotion was significantly less than that
of Sept4+/+ littermates for the time block of t = 85–110 (F1,30 = 4.172,
p < 0.05, n = 16 per genotype). The activity of Sept4/mice recovered
to the normal level at t = 130 and later.euron 53, 519–533, February 15, 2007 ª2007 Elsevier Inc. 523
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Septin, Dopamine Neuron, and a-SynucleinopathyFigure 5. Transgenic Supplementation
of Sept454 kDa Can Restore the Scarcity
of Presynaptic Molecules in Sept4/
Striatum
(A) Immunoblot showing the content of Sept4,
TH, DAT, a-synuclein (aS), and GAPDH in the
striatum of Sept4+/+ (WT), Sept4/ (KO),
and Sept4//Sept454 kDa transgenic mice
(KO/Tg1). Note that the scarcity of TH and
DAT in Sept4/ striatum was reversed by
adding back the Sept454 kDa transgene. The
asterisks indicate as of yet uncharacterized
processed forms (probably amino-terminal
truncations) of Sept454 kDa. Each lane con-
tained 50 mg protein.
(B) Immunohistochemistry for TH and DAT in
the striatum of Sept4/ (KO) and Sept4//
Sept454 kDa (KO/Tg1) mice. The signal intensi-
ties were restored in DA terminals, most obvi-
ously in the presynaptic varicosities (compare
also with Figures 4A and 4B). Bar: 20 mm; inset,
10 mm.
(C and D) Another line of transgenic mice,
Sept4-Tg2, exhibited mild hyper-dopaminergic
behaviors, i.e., disruption of PPI (C) and hyper-
sensitivity to methamphetamine in the open
field test (D). These behaviors, completely op-
posite to the hypo-dopaminergic phenotype
of Sept4/mice, suggest that Sept4 is a posi-
tive determinant of DA neurotransmission.i.e., hindlimb paralysis followed by quadriparesis, and
died within a week after the onset of the symptom. All the
symptomatic animals examined exhibited a-synuclein pa-
thology throughout the neuraxis. Of note, Sept4 involve-
ment in a-synuclein aggregates was visualized in this
model of a-synucleinopathy (Figure 7A).
We examined consequences of genetic loss of Sept4 in
aStg mice. Unlike non-Tg mice that lived more than 24
months with or without Sept4, aStg mice lacking Sept4
(aStg/S4/) had significantly shorter half survival time of
12 months as compared with17 months of the originalNaStg (aStg/S4+/+) mice (Figure 7B, p < 0.05). As reported on
the original aStg mice (Giasson et al., 2002), aStg/S4/
mice developed a-synuclein aggregates in the brainstem
nuclei and spinal ventral horns (Figure 7C). Intriguingly,
however, neuropathology of aStg/S4/mice was distinct
both qualitatively and quantitatively from that of aStg/S4+/+
mice in the following four ways.
(1) In the pontine reticular nuclei and spinal ventral
horns, aStg/S4/mice developed more amyloid deposits
of a-synuclein that contained a pathologically phosphory-
lated form (pSer129aS; Fujiwara et al., 2002) and wereFigure 4. Loss of Sept4 Attenuates Key Components of Dopamine Metabolism without Affecting the Morphology of DA Neurons
(A) Comparative immunohistochemistry revealed that the signal intensity for tyrosine hydroxylase (TH) and DAT were reduced in Sept4/ striatum.
Bar: 0.5 mm; inset, 20 mm.
(B) Network of axons and axon terminals of DA neurons were faintly labeled for TH but morphologically well-developed in Sept4/ striatum. TH-
positive structures were automatically extracted from digital microscopic images (e.g., bottom, left), and the total length of each binary image
was quantified and statistically analyzed (bottom, right). There was no difference in the total length of TH-positive structures by genotype. See
Experimental Procedures for details. Bar: 20 mm.
(C) Immuno-EM images for DAT in the dorsal striata of Sept4+/+ and Sept4/ mice. The fine morphology of DA neuron terminals was not different
between genotypes. Some DAT-positive presynaptic terminals containing synaptic vesicles are apposed to postsynaptic densities (PSDs, arrow-
heads) formed in the medium spiny neurons. S, asymmetric nondopaminergic (probably glutamatergic) synapses. The total DAT-positive area mea-
sured on immuno-EM images was comparable between Sept4+/+ and Sept4/ striata (Supplemental Figure S8). Bar: 0.5 mm.
(D and E) Mild reduction of TH content in Sept4/ striatum. Homogenates of Sept4+/+ and Sept4/ striata were blotted for TH, synapsin IIa, and
GAPDH. The TH/GAPDH ratio was significantly reduced in Sept4/ striatum (p < 0.05, n = 5 per genotype). Each lane contained 50 mg protein.
(F and G) As in (D) and (E), significant reduction of DAT content was confirmed in Sept4/ striatum (p < 0.01, n = 7 per genotype), which is consistent
with the immunohistochemical data in (A). Each lane contained 50 mg protein.
(H and I) In contrast, postsynaptic components were unaffected by the loss of Sept4. The intrinsic neurons in Sept4/ striatum were morphologically
normal in terms of the number of the medium spiny neurons (data not shown), immunohistochemistry for the dopamine type 2 receptor (D2R, [H]),
Golgi impregnation stain (Golgi, [H]), and the density of dendritic spines (I). Bar: top panels, 0.1 mm; middle panels, 20 mm; bottom panels, 3 mm.euron 53, 519–533, February 15, 2007 ª2007 Elsevier Inc. 525
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Septin, Dopamine Neuron, and a-SynucleinopathyFigure 6. Selective Scarcity of Proteins
for Dopamine Turnover and Dopamine
in Sept4/ Striatum
(A–C) Physical association of Sept4 with DAT,
aS, and syntaxin (Stx)-1A in the striatum. (A)
Sept4+/+ striatal homogenate was immunopre-
cipitated with preimmune rabbit IgG (negative
control) or the rabbit polyclonal antibody
H5C2 for Sept4, and probed for proteins as in-
dicated. (B and C) The same homogenate was
immunoprecipitated with mouse IgG (negative
control) and mouse monoclonal antibodies for
aS (B) or Stx-1A (C), and probed for Sept4.
(D) Immunoblot of Sept4+/+ (+/+) and Sept4/
(/) striatal homogenates for pre- and post-
synaptic proteins.
(E and F) The densitometric ratios of Stx-1A/
GAPDH (E) and aS/GAPDH (F) were slightly re-
duced in Sept4/ striata (n = 5 per genotype).
Because Stx-1A and aS are ubiquitous in the
brain, their scarcity in Sept4/ DA terminals
seems to be obscured.
(G) DA content measured by HPLC was signif-
icantly reduced in Sept4/ striatum by 25%
(p = 0.039, n = 5 per genotype). There was a
similar trend in the nucleus accumbens, an-
other target of nigral DA neurons (data not
shown).resistant to digestion by proteinase K (Figure 7C, top
panels, and Supplemental Figure S11). (2) In the spinal
ventral horns, aStg/S4/ mice exhibited a significant
loss of large motor neurons (>20 mm in diameter); how-
ever, smaller motor neurons and interneurons were not
affected (5–20 mm) (Figure 7C, bottom panels, and Fig-
ure 7D). (3) In the spinal ventral horns, aStg/S4/ mice
exhibited more severe astrocytic gliosis, indicative of on-
going inflammatory and degenerative processes (Supple-
mental Figure S10). (4) In the SNpc of aStg/S4/ mice,
pSer129aS-positive aggregates were formed in DA neu-
rons and swollen neurites (Figure 7F), and were not found
in aStg/S4+/+ mice. These data indicate that Sept4 can
be regarded as a suppressor of neurodegeneration by
a-synucleinA53T overload.526 Neuron 53, 519–533, February 15, 2007 ª2007 Elsevier Inc.Sept4 Can Suppress Pathological Modifications
of a-Synuclein In Vivo
To analyze the molecular basis of the enhancement of
a-synuclein pathology by the loss of Sept4, we examined
the biochemical status of a-synuclein in graded extraction
(i.e., in Triton-soluble, sodium dodecyl sulfate- [SDS-] sol-
uble, and SDS-insoluble fractions) of the spinal cord. In
each fraction of young asymptomatic mice, a-synuclein
was detected mainly as the native form of 17 kDa (aS
in Figure 7E, left top panel). Intriguingly, the SDS-insoluble
fraction of aged, symptomatic mice additionally contained
putative crosslinked dimers [(aS)2] and other modified
forms, high-molecular-weight smears (HMWaS), and ag-
gregates that stuck at the top of the resolving gel (arrow
in Figure 7E, right top panel). These aberrant a-synuclein
Neuron
Septin, Dopamine Neuron, and a-Synucleinopathyspecies were more prominent in symptomatic aStg/S4/
mice than in older symptomatic aStg/S4+/+mice (compare
the second and third lanes from the right in Figure 7E, right
top panel). The modified a-synuclein species were remi-
niscent of those found in human a-synucleinopathies;
i.e., the24 kDa bandmay correspond toO-glycosylation
(Shimura et al., 2001) or another modification (Tofaris
et al., 2003), and the 40 kDa double bands may repre-
sent crosslinked homodimers and/or other modified spe-
cies (Kahle et al., 2001). None of these modified species
were labeled for ubiquitin (data not shown).
Among other biochemical abnormalities, accumulation
of pSer129aS in the SDS-insoluble fraction was the most
significant characteristic of symptomatic aStg/S4/
mice (Figure 7E, right second panel). The amount of insol-
uble pSer129aS was positively correlated with the severity
of neuropathology in the spinal cord. Thus, SDS-insoluble
pSer129aS seems to correspond to the protease-resistant
amyloid deposits (Figure 7C and Supplemental Fig-
ure S11). aStg mice hemizygous for Sept4 (aStg/S4+/)
contained an intermediate amount of pSer129aS in each
fraction (Supplemental Figure S12), indicating that the
dosage of Sept4 is a determinant of a-synuclein modifica-
tion. Importantly, symptomatic aStg/S4/mice contained
SDS-insoluble pSer129aS not only in the spinal cord, but
also in the forebrain (data not shown) and the nigral DA
neurons in the midbrain (Figures 7F–7H).
Taken together, aggregation and Ser129 phosphoryla-
tion of a-synuclein seem to be central events underlying
the neurodegeneration of aStg mice, and these patholog-
ical modifications were obviously enhanced by the loss of
Sept4.
Direct Interaction with Sept4 Prevents
Self-Aggregation and Ser129 Phosphorylation
of a-Synuclein In Vitro
How does Sept4 suppress neurotoxicity caused by
chronic overload of a-synuclein? It has been hypothesized
that self-aggregation of a-synuclein that occurs in various
pathological processes generates neurotoxic species
(Dawson and Dawson, 2003), and that Ser129 phosphory-
lation can facilitate the process (Fujiwara et al., 2002).
Thus, we tested in vitro whether thesemodifications could
be suppressed by Sept4. First, we confirmed that a-synu-
clein and Sept4 directly associate in vitro (Figure 8A). Sec-
ond, we found that Sept4 suppressed self-aggregation of
a-synucleinA53T into SDS-resistant HMW species (Fig-
ure 8B). Third, Sept4 partially interfered with Ser129 phos-
phorylation of a-synucleinA53T by a ubiquitous Ser/Thr-
kinase, casein kinase II (CKII; Fujiwara et al., 2002)
(Figure 8C). However, Sept4 did not essentially inhibit
the kinase activity of CKII when casein was used as the
substrate (Supplemental Figure S13). When the data
were taken together, we concluded that direct interaction
with Sept4 can prevent a-synuclein from self-aggregation
(as has been proposed for another LB component, aB-
crystallin) (Rekas et al., 2004), and may shield a-synuclein
from Ser129 phosphorylation by CKII and other kinases.NeSuch protective effects on a-synuclein modifications, per-
haps by steric hindrance and/or conformational changes,
may be more effective in the physiological situation where
Sept4, DAT, and Stx-1A are in close proximity to a-
synuclein (Figure 6A).
DISCUSSION
Sept4/ Mice Revealed a Physiological Septin
Function in the Brain
Septins have been implicated in exocytosis based on their
presynaptic localization (Kinoshita et al., 2000; Xue et al.,
2004), physical and functional interaction with syntaxins
(Beites et al., 1999, 2005), and aberrant exocytosis in
blood platelets lacking Sept5 (Dent et al., 2002). However,
previous attempts to address septin functions in the brain
with Sept3/, Sept5/, or Sept6/ mice were unsuc-
cessful, probably due to compensation by their function-
ally redundant paralogs (Fujishima et al., 2007; Peng
et al., 2002; Ono et al., 2005). We employed a comprehen-
sive behavioral test as a means of unbiased screening for
neurological defects in Sept4/mice. This approach has
successfully pinpointed a specific neurological phenotype
by the loss of septin function, i.e., the attenuation of ni-
grostriatal DA transmission. While DA neurons were func-
tionally affected by the loss of Sept4, non-DA neurons
were unchanged. This intriguing form of selectivity may
be due to the absence of redundant septin species, and/
or a specific requirement of Sept4 subunit, in DA neurons.
Sept4 Is Required as a Component of Presynaptic
Scaffolds in DA Neurons
Extending our previous finding of Sept4 involvement in
LBs (Ihara et al., 2003), the present study has revealed
Sept4 insufficiency in presynaptic DA terminals in the hu-
man striatum affected with sporadic PD. This is partly due
to sequestration of Sept4 into a-synuclein aggregates,
and partly as a result of neuronal loss. To investigate the
pathophysiological impact of Sept4 depletion in PD, we
created and investigated several mouse models: the
genetic loss of Sept4 attenuated, an excess of Sept4 en-
hanced, and a transgenic Sept4 supplementation ofSept4
null mice normalized nigrostriatal DA transmission. These
results suggest a positive role for Sept4 in dopamine turn-
over.
The hypo-dopaminergic behavioral deficits observed in
Sept4/ mice were attributed not to morphological
anomalies of DA neurons but to an insufficiency of specific
components in DA terminals. The levels of DAT, TH,
a-synuclein, Stx-1A, and another tSNARE component
depended more or less on the amount of Sept4. Sept4 di-
rectly or indirectly interacts with most of these molecules
in the striatum. Considering the physical association of
thesemolecules, Sept4 can be regarded as a pivotal com-
ponent of the presynaptic scaffold for the machinery of
dopamine release and reuptake. The detailed organization
of suchmachinery would be an intriguing subject for future
studies.uron 53, 519–533, February 15, 2007 ª2007 Elsevier Inc. 527
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Sept4 and a-Synuclein
a-Synuclein, a presynaptic protein of unknown physiolog-
ical function, is a soluble, natively unfolded polypeptide.
Our study demonstrated physical interaction between
a-synuclein and Sept4 in presynaptic terminals of nigral
DA neurons. A recent report proposed that a-synuclein
might act as a molecular chaperone for some tSNARE
components, as excessive a-synuclein prevented the pre-
synaptic degeneration in CSPa/ mice (Chandra et al.,
2005). The close association of Sept4 with both a-synu-
clein and tSNAREs suggests that Sept4 is involved in
the proposed scheme. The similar hypo-dopaminergic
phenotypes observed in Sept4/ and a-synuclein/
mice (Abeliovich et al., 2000) also support a functional
convergence of these molecules.
Under pathological conditions where a-synuclein is
overloaded and/or displaced in DA neurons, the polypep-
tide is subject to various modifications. Above all, Ser129
phosphorylation commonly found in LBs/Lewy neurites
is considered the hallmark of a-synucleinopathies be-
cause pSer129aS is absent in normal presynaptic termi-
nals and prone to form aggregates in vitro (Fujiwara
et al., 2002). Our data suggest that Sept4 and a-synuclein
are components of presynaptic complexes at the DA ter-Nminals, and that lack of the physiological association with
Sept4 facilitates self-aggregation and Ser129 phosphory-
lation of a-synuclein.
How Is Sept4 Involved in a-Synucleinopathy?
This study demonstrated that aStg and aStg/S4/ mice
provide important insights into the biochemical processes
underlying a-synucleinopathies. We have demonstrated
that endogenous Sept4 is involved in a-synuclein aggre-
gates formed in aStg mice (Figure 7A) as well as humans
with sporadic PD (Ihara et al., 2003; Figure 1B–1D). The
increased a-synuclein aggregation in aStg/S4/ mice in-
dicates that Sept4 incorporation is a secondary event that
can suppress further a-synuclein aggregation. Based on
these and other findings, we propose a model for a-synu-
cleinopathies (Figure 8D), whereby incipient a-synuclein
aggregates formed in DA neurons adsorb Sept4. This
may retard LB formation, but it eventually depletes
Sept4 from the presynaptic terminals (Figure 1K–1U). As
seen in aStg/S4/ mice, Sept4 insufficiency attenuates
DA transmission and subjects a-synuclein to toxic conver-
sions. Thus, pathological a-synuclein/Sept4 interaction in
LBs and dissociation of their physiological interaction at
presynaptic terminals may constitute a vicious cycle that
further disrupts homeostasis of DA neurons in PD.Figure 7. Loss of Sept4 Exacerbates Neuropathology and Aberrant a-Synuclein Modifications in a-synucleinA53T Transgenic Mice
(A) Representative a-synuclein aggregates formed in a symptomatic aStg/S4+/+ mouse, 12 months old (m.o.). Coaggregation of Sept4 (red) with aS
(green), as seen in human LBs, is recapitulated in this model of a-synucleinopathy. Bar, 20 mm.
(B) (Left) A chart showing the age of onset of hindlimb paresis in aStgmice with or without Sept4. The Sept4+/+ and Sept4/ non-Tg mice (green and
pink plots, respectively) never showed the symptom. Intriguingly, however, aStg/S4/ mice (red) developed hindlimb paresis and died 3–4 months
earlier than the original aStg/S4+/+ mice (blue; Giasson et al., 2002). (Right) A 12 m.o. aStg/S4+/+ presymptomatic mouse rearing on its aStg/S4/
littermate, which had developed hindlimb paresis (arrows).
(C) (First and second panels from top) Representative images of the spinal ventral horn comparatively immunostained for pSer129aS (brown) or labeled
for total aS after proteinase K digestion (green fluorescence). Each inset shows a pSer129aS-positive large motor neuron in the ventral horn (arrow-
heads); compare the levels of pSer129aS and misfolded aS deposits in a 12 m.o. presymptomatic aStg/S4+/+ mouse (left panels), a 16 m.o. symptom-
atic aStg/S4+/+ mouse (middle panels), and a 12 m.o. symptomatic aStg/S4/mouse (right panels). Bar: upper panels, 40 mm; lower panels, 200 mm.
Vh, ventral horn; Vwm, ventral white matter; Cc, central canal. (Third and fourth panels from top) Representative Nissl-stained sections of the spinal
cord from the same animals. Note a recognizable reduction of large motor neurons in the symptomatic aStg/S4/ mouse (right panels). Bar: upper
panels, 200 mm; lower panels, 60 mm.
(D) The counts of large neurons (left) and small to medium-sized neurons (right) in the spinal cord sections from presymptomatic aStg/S4+/+ mice
(white bars, 5–8m.o.), symptomatic aStg/S4+/+ mice (blue bars, 12–18m.o.), and symptomatic aStg/S4/mice (red bars, 10–14m.o.). Note that large
neurons, classified as a motor neurons, were selectively and significantly lost in aStg/S4/ mice (*p < 0.05, n = 4 per genotype).
(E) (Left, top) The spinal cord homogenates of young presymptomatic aStg/S4+/+ and aStg/S4/ littermates were fractionated into Triton (X-100)-
soluble, SDS-soluble, and SDS-insoluble components. Each fraction was immunoblotted for total aS, pSer129aS, Sept4, and GAPDH. The SDS-
insoluble fraction of aStg/S4/mice consistently contained low- to high-molecular-weight (HMW) smear of aS (rightmost lane). (Left, second panel)
At this age, aS was barely Ser129 phosphorylated in any fraction/genotype measured. Thus, Ser129 phosphorylation is preceded by some other mod-
ifications that cause the mobility shift of aS. (Right, top) Likewise, aStg/S4+/+ (17 m.o.) and aStg/S4/ (12 m.o.) mice with or without symptoms were
analyzed. In addition to prominent HMW smears of aS, the SDS-insoluble fractions of the symptomatic animals of each genotype contained larger
aggregates at the top of the resolving gel (arrow) and above in the stacking gel. However, only symptomatic aStg/S4/mice contained heavy bands
of modified aS (p40, crosslinked dimer, p24; arrowheads) in the SDS-insoluble fraction. (Right, second panel) The aged symptomatic animals
commonly contained pSer129aS in the Triton-soluble and SDS-soluble fractions. In addition, symptomatic aStg/S4/ mice contained significant
pSer129aS (monomer and higher molecular weight species; arrowheads) in the SDS-insoluble fraction. (Right, third panel) Sept4 in the SDS-insoluble
fraction was increased and smeared in symptomatic aStg/S4+/+ mice, reflecting some biochemical modifications and coaggregation with aS.
(F) Double-label immunofluorescence for TH (red) and aS or pSer129aS (green) in aStg/S4/ SNpc. aS/pSer129aS-positive aggregates in DA neurons,
which were reminiscent of LBs (arrows) and Lewy neurites (arrowheads), were often found in aStg/S4/ ventral midbrain, but never in aStg/S4+/+mice
(data not shown). Bars: upper panels, 40 mm; lower panels, 20 mm.
(G) The ventral midbrains (containing DA neurons in SNpc and VTA) were analyzed as in (E). Intriguingly, each fraction of symptomatic aStg/S4/mice
contained more pSer129aS (monomer and higher molecular weight species; arrowheads) than that of aStg/S4+/+ mice.
(H) Experiments of (E) and (G) were triplicated and quantified. The densitometric ratio of pSer129aS/GAPDH in the SDS-insoluble fraction was signif-
icantly higher in the spinal cord and ventral midbrain of symptomatic aStg/S4/ mice (/) as compared with symptomatic aStg/S4+/+ mice (+/+;
*p < 0.01, n = 3).euron 53, 519–533, February 15, 2007 ª2007 Elsevier Inc. 529
Neuron
Septin, Dopamine Neuron, and a-SynucleinopathyFigure 8. Sept4 Directly Interacts with a-Synuclein and
Suppresses Its Self-Aggregation and Ser129 Phosphorylation
In Vitro
(A) Sept4 directly interacts with aS. Mixtures of aS (wild-type),
Sept454 kDa, or BSA in PBS were ultracentrifuged at 440,000 3 g for
30 min. The supernatant (S) and the pellet (P) of each mixture were an-
alyzed by SDS-PAGE and stained with Coomassie Brilliant Blue (CBB).
(From left to right lanes) aS alone was soluble (S). Most of Sept4 was
sedimented (P), perhaps due to homo-oligomerization. aS interacted
with Sept4 and interferedwith the sedimentation. BSA, another soluble
protein used as a control, did not show such effects. These data indi-
cate direct association between Sept4 and aS.
(B) Sept4 can suppress self-aggregation of aS in vitro. (Top andmiddle
panels) Recombinant human a-synucleinA53T (aS) was incubated in
a physiological buffer with recombinant Sept448 kDa or BSA. Each
reaction was resolved by SDS-PAGE and CBB stained. (Bottom panel)
The same reactions were immunobloted for total aS. After 44 hr incu-
bation without Sept4, a fraction of aS was self-aggregated or oligo-
merized as HMW bands. In contrast, HMW bands of aS were not
formed in the presence of Sept4. A 34 kDa band (*) represents aS
dimers formed in E.coli (Masuda et al., 2006).
(C) Sept4 can mildly interfere with casein kinase II (CKII)-mediated
phosphorylation and other modifications of a-synuclein in vitro. (Top
and middle panels) aSA53T, CKII, and ATP were incubated in a buffer530 Neuron 53, 519–533, February 15, 2007 ª2007 Elsevier Inc.Intriguingly, DA neurons in aStg mice developed a-syn-
uclein aggregates only in the absence of Sept4 (Figures
7F–7H). Thus, loss of Sept4 is a critical event for the devel-
opment of a-synuclein pathology in DA neurons, although
it appears additional insults and/or aging are necessary for
them to die. When compared with mice, human DA neu-
rons are more sensitive to various insults, including a-syn-
uclein overload (LaVoie et al., 2005; Moore et al., 2005).
Thus, Sept4 depletion found in humans (Figures 1K–1U)
should impact DA neurons more seriously.
Loss of Sept4 Function versus Gain of Toxic Effects
Sept4-Tg1 and Sept4-Tg2 transgenic mice generated in
this study have demonstrated that mild chronic overload
of Sept4 is cytotoxic to various cell lineages. This is con-
sistent with previous findings that acute Sept5 overex-
pression can damage DA neurons in the rat (Dong et al.,
2003). Thus, both insufficiency and excess of Sept4 could
perturb the homeostasis of DA neurons, ultimately leading
to disorganization of their presynaptic terminals—another
intriguing similarity to a-synuclein (Abeliovich et al., 2000;
Chandra et al., 2005; Moore et al., 2005). As for sporadic
PD cases, however, we have not obtained any samples
that contained excessive Sept4 in the striatum. Thus,
Sept4 overload may not be relevant in the etiology of
sporadic PD.
In summary, our present as well as previous studies
have established physiological and pathological roles of
Sept4 in the nigral DA neurons. Future studies should
characterize the presynaptic complex containing Sept4
and other key molecules. From a pathological aspect, un-
raveling the precisemolecular mechanism bywhich Sept4
suppresses the a-synuclein toxicity may help develop
neuroprotective strategies for PD.
EXPERIMENTAL PROCEDURES
Analyses of Clinical Samples
Postmortem human brain tissues were dissected within 6 hours post-
mortem under signed informed consent from the patients’ relatives,
and in accordance with the guidelines of ethics committees of Kyoto
University and Juntendo University. Tissues for immunohistochemistry
were fixed at Kyoto University Hospital. Donor subjects included 16 PD
with recombinant Sept448 kDa or BSA, and analyzed as in (A). (Bottom
panel) The same reactions were immunobloted for pSer129aS. Sept4
mildly interfered with Ser129phosphorylation of aSA53T and the forma-
tion of HMWspecies containing pSer129aS. These data also suggested
that pSer129aS is more prone to self-aggregation than aS (compare
the rightmost lanes of B and C). Parallel reactions using wild-type
aS (instead of aSA53T) gave similar results (data not shown). Data in
(A)–(C) are representative of at least three experiments.
(D) A working model of PD pathophysiology including Sept4 as a novel
player: a-synuclein aggregates (LB) formed by various pathological
causes commonly involve Sept4. The involvement may retard the pro-
cess while it sequesters and depletes Sept4 fromDA nerve terminals in
the striatum. The insufficiency of Sept4 in the presynaptic scaffold re-
duces the critical components for DA transmission, which contributes
to DA dysfunction. In addition, an excess of a-synuclein in the absence
of Sept4 facilitates its oligomerization, phosphorylation, and other
modifications, which generate neurotoxic species.
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Septin, Dopamine Neuron, and a-Synucleinopathypatients (age range, 62–87 years old [y.o.]; mean, 73.7 y.o.) and 16 pa-
tients who died of nonneurological diseases (47–94 y.o.; mean, 64.1
y.o.). The frontal cortex and striatal tissues for immunoblot were dis-
sected at Kyoto University Hospital and Juntendo Hospital, respec-
tively, quickly frozen, and preserved at 80C until protein extraction
(see Supplemental Figure S1 for clinical data). In each case, the clinical
diagnosis was confirmed neuropathologically, mostly by the presence
of nigral LBs by hematoxylin-eosin stain. For immunohistochemistry,
the brains fixed with 4% paraformaldehyde were sliced coronally,
and the cerebral region containing the basal ganglia was isolated
and embedded in paraffin, sectioned (6 mm thick), and subjected to
immunohistochemistry as previously described (Ihara et al., 2003).
The immunostained sections were optically scanned (16 bit, 600
dpi), and the integrated densities for a selected area (2 mm 3 2 mm)
were calculated with software (MultiGauge 2.0, Fujifilm, Japan). In
each sample, three or more areas of the putamen and insular cortex
were measured to obtain the average densitometric values.
Double-Label Immunofluorescence
Double-labeling immunofluorescence studies were performed by
incubating human and mouse tissue sections with anti-Sept4, -DAT,
or -a-synuclein antibodies. Fluorescein isothiocyanate- or rhodamine-
conjugated appropriate secondary antibodies were applied. See the
Supplemental Data for details.
Comparative Morphometric Analyses of DA Nerve Terminals
at Light Microscopy and EM Levels
High-contrast images of TH-stained mouse striatal sections were
captured and digitized by a light microscope with a CCD camera.
The digital images were binarized with an arbitrary threshold, and
the total length of the TH-positive neurites was calculated using Neuro-
cyte Image Analyzer, ver. 1.5 (Kurabo, Japan). For the EM-level mea-
surement of DA nerve terminal area, we used immuno-EM images of
TH and DAT. TH- or DAT-positive areas in each digital EM image dis-
played on a computer screen were encircled manually using a digital
pen tablet system, Intuos3 (Wacom Technology, Japan). The total
encircled area was automatically calculated with graphic software
(Scion, ver. b 4.0.2.). For each marker, 24 fields from corresponding
regions of dorsal striata of Sept4+/+ and Sept4/ littermates were
randomly sampled and analyzed blindly.
Immunoblotting and Immunoprecipitation
For immunoblotting, striatal tissues punched out from coronal brain
slices of 3–5 m.o. mice were homogenized and sonicated in buffer A
(10 mM Tris-HCl [pH 7.6], 1% Triton X-100, 0.15 M NaCl, 0.1% sodium
deoxycholate, 0.1% sodium dodecyl sulfate), and then centrifuged at
15,000 3 g at 4C for 0.5 hr. The protein content of the supernatants
was quantified using the Bradford method, and 50 mg of protein was
denatured with an equal volume of 2 3 SDS sample buffer and sub-
jected to a standard immunoblot assay using peroxidase-conjugated
secondary antibodies and an ECL chemiluminescence kit (GE Health-
care Biosciences). The amount of immunoreactive proteins was esti-
mated by densitometry (see above). For coimmunoprecipitation of
proteins, tissues were extracted with buffer B (0.1 M Tris-HCl [pH
7.6], 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, prote-
ase inhibitors). After centrifugation, the supernatants were diluted with
nine volumes of lysis buffer B0 without Triton X-100, resulting in a final
concentration of 0.1%. Each lysate was incubated with various anti-
bodies and Affi-Prep Protein A beads (Bio-Rad) at 4C for 1 hr. Immu-
noprecipitates on the beads were washed five times with lysis buffer A,
and analyzed by immunoblot.
Animals and Experimental Design
All animal procedures were performed in accordance with the guide-
lines of the Animal Use and Care Committee of Kyoto University. Het-
erozygousSept4+/micewere backcrossedwith C57BL/6J for at least
ten generations (Ihara et al., 2005).Sept4/mice and the control litter-Nemateswere generated fromSept4+/mice. The original aStgmicewere
bred with Sept4/ mice to generate aStg/S4+/ mice, which were
inbred to generate aStg/S4+/+, aStg/S4+/, and aStg/S4/ littermates.
Biallelic Tg mice were identified by real-time PCR analysis and verified
by backcrossing. All comparisons were made between littermates to
minimize confounding effects by different genetic backgrounds. All
behavioral tests were carried out on male mice (2–2.5 m.o.) (Miyakawa
et al., 2001). Mice were given a light/dark cycle of 12 hr (lights on at
7 a.m.) and food and water ad libitum. Behavioral testing was per-
formed between 9 a.m. and 6 p.m. except for the home cage social
interaction test. After each test, all apparatuses were cleaned with
acidic hypochlorous solution that eliminated mouse odors. Mouse
brains were dissected after deep anesthesia with sodium pentobarbi-
tal (50 mg/kg, i.p.) with or without transcardial perfusion with 0.01 M
phosphate-buffered saline (PBS). For histological analysis, mice
were additionally perfusedwith 4%paraformaldehyde and 0.2%picric
acid in 0.1 M PBS. Tissues from symptomatic aStg mice were dis-
sected within a few days after the onset of hindlimb paresis to prevent
suffering for ethical reasons and to minimize temporal changes that
might influence the results.
Biochemical Fractionation of Neural Tissues
by Graded Extraction
The forebrain, brainstem, and spinal cord from aStg/S4+/+ or aStg/
S4/ mice (5–16 m.o.) were dissected, weighed, and homogenized
by sonication in 3 ml/g of buffer C (10 mM Tris-HCl [pH 7.6], 0.15 M
NaCl, 1% Triton X-100, and protease inhibitors). The supernatant, after
centrifugation at 15,000 3 g at 4C for 0.5 hr, was labeled as ‘‘Triton-
soluble fraction.’’ The pellet was sonicated and re-extracted with
1 ml/g of buffer D (10 mM Tris-HCl [pH 8.0], 0.15 M NaCl, 1% Triton
X-100, 0.5% sodium deoxycholate, and 0.1% SDS) and fractionated
by centrifugation at 15,000 3 g at 4C for 0.5 hr, and the supernatant
was labeled as ‘‘SDS-soluble fraction.’’ The pellet was dissolved by
sonication and boiling in buffer E (3% SDS and 5% b-mercaptoetha-
nol, 1 ml/g pellet), and the lysate was termed ‘‘SDS-insoluble fraction.’’
The amounts proportional to the original brain weight were loaded on
separate lanes and each fraction was analyzed by immunoblot.
In Vitro Sedimentation, Aggregation,
and Phosphorylation Assays
The recombinant His6-tagged mouse Sept4
54 kDa was prepared in Sf9
cells (Kinoshita et al., 2002). For recombinantmouse Sept448 kDa, GST-
fusion protein was expressed in E.coli with a plasmid, pGEX-6P (GE
Healthcare Biosciences). After purification of GST-Sept448 kDa with
glutathione-agarose beads, GST-PreScission protease (Roche) was
added to the beads to cleave the GST tag and release untagged
Sept448 kDa. For sedimentation assay, 20 ml reactions of recombinant
human aS (wild-type, 4 mg, BioMol), recombinant mouse Sept454 kDa
(2 mg), and/or BSA (2 mg, Sigma) in PBS were incubated at 4C for
16 hr. Each reaction was ultracentrifuged at 4C at 440,000 3 g for
30 min. The supernatants and the pellets were analyzed by SDS-
PAGE/CBB. For self-aggregation and phosphorylation assays, re-
combinant human aS (A53T mutant, 100 mg, BioMol) was incubated
in 100 ml reactions of 30mM Tris-HCl (pH 7.5) and BSA (100 mg, Sigma)
or recombinant Sept448 kDa (20 mg) at 37C. For phosphorylation as-
says, 4 mMMgCl2, 2 mM ATP, and CKII (500 U, New England Biolabs)
were added. The reactions sampled at 0, 2, and 44 hr were analyzed by
SDS-PAGE/CBB, and analyzed by immunoblot for aS or pSer129aS.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/53/4/519/DC1/.
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